Tarsus Pharmaceuticals Inc.

TARS

Held by 9 specialist biotech funds

High Convergence

9 funds opened new positions. Next phase2 readout (lotilaner): Dec 2026. Short interest: 11.6% of float.

BiotechnologyCEO: Bobak R. AzamianIPO: 2020Website ↗

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Recent News & Research

PubMed

Efficacy of Credelio Quattro™ chewable tablets containing lotilaner, moxidectin, pyrantel, and praziquantel against Ctenocephalides felis and Rhipicephalus sanguineus infestations on dogs.

I appreciate the request, but I need to flag an important issue: This article is dated April 27, 2026—a future date that hasn't occurred yet. This appears to be either a data error or a hypothetical scenario. Assuming you meant a past publication date, here's the investor relevance: **If this were a legitimate Tarsus study:** This would demonstrate clinical efficacy for Credelio Quattro in veterinary parasitology, supporting market adoption and label claims for a combination product. Strong efficacy data typically translates to competitive positioning, pricing power, and revenue growth in the animal health segment—material for revenue forecasting and market share analysis. **For actual investment tracking of TARS:** I'd recommend verifying the correct publication date and reviewing Tarsus's current pipeline focus (which centers on human dermatology/ophthalmology), as this veterinary dermatology asset may or may not

Apr 27, 2026

PubMed

Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs.

# Tarsus Pharmaceuticals - Research Summary **Key Finding:** Credelio Quattro demonstrates efficacy in preventing heartworm disease and treating multiple parasitic infections in dogs through a single chewable formulation. **Investor Implications:** This represents a line extension of Tarsus's existing Credelio portfolio, combining four active ingredients to address multiple canine parasites in one dose—potentially improving compliance and capturing market share from multi-product regimens. The broad-spectrum approach addresses a significant veterinary market need, though commercial impact depends on pricing strategy, veterinary adoption rates relative to alternatives, and whether this addresses a genuine market gap versus existing combination products already available in the animal health space.

Apr 6, 2026

Tarsus Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research